by Elena Iemma | Mar 29, 2024 | Featured, News
PROVIDENCE, RI, April 1, 2024 /PRNewswire/ — In the pursuit of developing novel biologic entities, scientists harnessing the power of AI and generative biology depend on computational tools for predicting and managing immunogenicity risk – a critical...
by Elena Iemma | Jan 30, 2024 | Featured, Thinking Out Loud -Blog
It’s Post-Pandemic and we’re back on the road traveling to the 4 corners of the Earth. Where will we get to see you? Here’s a list of upcoming events, and because … what’s travel without great food? … I’ve included some...
by Elena Iemma | Dec 20, 2023 | Featured, News
PROVIDENCE, RI, December 20, 2023 /PRNewswire/ — EpiVax, Inc. (“EpiVax”), an internationally recognized leader in the field of immunogenicity, today announced that Eisai Co. Ltd. (“Eisai”) has licensed EpiVax’s ISPRI toolkit for immunogenicity risk assessment of...
by Elena Iemma | Nov 27, 2023 | Featured, Thinking Out Loud -Blog
This is a two-way street Hey Hey, Hallo, Hola, Ciao, Namaste, Hello, Bonjour, Konnichiwa! When do you do your ‘thinking’ about the day? Do you do it while running? Well, I was thinking about you guys on my runs this week. I am finally back in Providence,...
by Elena Iemma | Nov 20, 2023 | Featured, News
EpiVax CEO Annie De Groot was one of three plenary session speakers at a recent international forum on vaccines organized by Joon Rhee. Her topic was ‘Better, Safer, and Personalized Vaccines will Result from Human + Artificial Intelligence’. Other speakers...
by Elena Iemma | Aug 10, 2023 | Featured, News
PROVIDENCE, RI, August 10, 2023 /PRNewswire/ — EpiVax Inc. announces the publication of results from a research collaboration with the Food and Drug Administration aimed at streamlining generic drug evaluations. The research, initiated in 2018 with a $1M...